Last reviewed · How we verify
CB-Cabo
At a glance
| Generic name | CB-Cabo |
|---|---|
| Also known as | combo CB-839 and cabozantinib |
| Sponsor | Calithera Biosciences, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (PHASE2)
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CB-Cabo CI brief — competitive landscape report
- CB-Cabo updates RSS · CI watch RSS
- Calithera Biosciences, Inc portfolio CI